A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2011
08/11/2011	US20110195125 Nanoparticles For Drug Delivery To The Central Nervous System
08/11/2011	US20110195123 Methods, compositions and systems for local delivery of drugs
08/11/2011	US20110195122 Extended Release Formulation
08/11/2011	US20110195120 Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride
08/11/2011	US20110195119 Controlled release metformin formulations
08/11/2011	US20110195118 Process for Producing Oral Dosage Forms With Controlled Release
08/11/2011	US20110195117 Controlled release compositions of ropinirole
08/11/2011	US20110195116 Rate modulated delivery of drugs from a composite delivery system
08/11/2011	US20110195115 Hydrophilic amino acid-containing preparation having improved taste
08/11/2011	US20110195114 Transdermal delivery systems for active agents
08/11/2011	US20110195111 Aqueous compositions and methods
08/11/2011	US20110195110 Urea compounds useful in the treatment of cancer
08/11/2011	US20110195109 Adhesive skin patch and packaged product
08/11/2011	US20110195097 Composition and dosage form comprising a particle formulation and suspending vehicle
08/11/2011	US20110195096 Compositions and methods for treating inflammatory disorders
08/11/2011	US20110195095 Injectable nanoparticulate olanzapine formulations
08/11/2011	US20110195094 Triazole compounds that modulate hsp90 activity
08/11/2011	US20110195089 Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
08/11/2011	US20110195072 Non-neuroendocrine cancer therapy
08/11/2011	US20110195071 Therapy-enhancing glucan
08/11/2011	US20110195066 Quinoline inhibitors of tyrosine kinase
08/11/2011	US20110195063 Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
08/11/2011	US20110195061 Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
08/11/2011	US20110195049 Compositions and methods for treating multiple sclerosis
08/11/2011	US20110195042 Compositions, Methods and Kits Useful for Treating a Respiratory Symptom
08/11/2011	US20110195040 Method for preventing the formation of adhesions following surgery or injury
08/11/2011	US20110195039 Hair building solid agent
08/11/2011	US20110195032 Menthylcarboxamides and Their Use as Cooling Agents
08/11/2011	US20110195031 Methods for the use of progestogen as a glucocorticoid sensitizer
08/11/2011	US20110195030 Nanoparticle compositions comprising liquid oil cores
08/11/2011	US20110195026 Protein
08/11/2011	US20110195025 Anionic oligosaccharide conjugates
08/11/2011	US20110195024 Isatin derivatives for use as in vivo imaging agents
08/11/2011	US20110195018 Low molecular weight thyroid stimulating hormone receptor (tshr) agonists
08/11/2011	US20110192748 Administration of Dipeptidyl Peptidase Inhibitors
08/11/2011	US20110192493 Liquid Pharmaceutical Formulations of Palonosetron
08/11/2011	DE10347824B4 Pharmazeutische oder kosmetische Zusammensetzung zur Behandlung der Haut A pharmaceutical or cosmetic composition for treating the skin
08/11/2011	DE102010026879A1 Transdermal system, useful for indicating and preventing multiple sclerosis, immunomodulator including quinolines or isoxazoles, metabolite forming groups, skin protective layer, a reservoir and a carrier impermeable to active substance
08/11/2011	DE102010007722A1 Progesteronrezeptorantagonisten Progesterone receptor antagonists
08/11/2011	DE102010007719A1 Progesteronrezeptorantagonisten Progesterone receptor antagonists
08/11/2011	DE102010007562A1 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide Dermatological pharmaceutical composition suitable for oligonucleotides
08/11/2011	DE102010007281A1 Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger New aminoalkyl-oxazole and aminoalkyl thiazolecarboxamides and their application for the stimulation of endogenous situ regeneration of hair cells in the organ of Corti in the inner ear in mammals
08/11/2011	CA2826548A1 Crystallization method and bioavailability
08/11/2011	CA2824869A1 Optically active 2-hydroxytetrahydrothienopyridine derivatives, preparation method and use in manufacture of medicament thereof
08/11/2011	CA2824843A1 Dosing regimens for treating and preventing ocular disorders using c-raf antisense
08/11/2011	CA2789279A1 1,2,4-triazine-4-amine derivatives
08/11/2011	CA2789151A1 Pyridazine derivatives useful as cannabinoid-2 agonists
08/11/2011	CA2789144A1 Compositions and methods for treating obesity and obesity-related conditions
08/11/2011	CA2789093A1 Compounds for treating respiratory syncytial virus infections
08/11/2011	CA2789038A1 Selective reduction of allelic variants
08/11/2011	CA2789021A1 Hetaryl-[1,8]naphthyridine derivatives
08/11/2011	CA2789013A1 Novel aminoalkyloxazole- and aminoalkylthiazolecarboxylic acid amides as regeneration-promoting substances for sensory organs and post-mitotic tissue
08/11/2011	CA2789006A1 Extended release formulations of rasagiline and uses thereof
08/11/2011	CA2789005A1 Selective reduction of allelic variants
08/11/2011	CA2789001A1 Method for treatment of lacto-n-biose-containing solution
08/11/2011	CA2788986A1 Pyrrolidine derivatives
08/11/2011	CA2788983A1 Synthesis of dgjnac from d-glucuronolactone and use to inhibit alpha-n-acetylgalactosaminidases
08/11/2011	CA2788969A1 Sgc stimulators or sgc activators alone and in combination with pde5 inhbitors for the treatment of cystic fibrosis
08/11/2011	CA2788907A1 Selective androgen receptor modulators
08/11/2011	CA2788782A1 Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
08/11/2011	CA2788766A1 Treatment of respiratory disorders
08/11/2011	CA2788749A1 Pharmaceutical composition comprising n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
08/11/2011	CA2788730A1 Read through inducer, and therapeutic agent for nonsense-mutation-type genetic diseases
08/11/2011	CA2788720A1 Medicament for treating and/or preventing cancer
08/11/2011	CA2788684A1 Treatment skin disorders
08/11/2011	CA2788682A1 Compositions and methods for enhanced parvovirus transduction
08/11/2011	CA2788678A1 Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
08/11/2011	CA2788669A1 Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
08/11/2011	CA2788663A1 Taxane-and taxoid-protein compositions
08/11/2011	CA2788587A1 Fatty acid amide hydrolase inhibitors
08/11/2011	CA2788569A1 Antimicrobial compounds
08/11/2011	CA2788554A1 Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same
08/11/2011	CA2788416A1 Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor
08/11/2011	CA2788115A1 Compositions and methods for reducing appearance of under-eye dark circles
08/11/2011	CA2788071A1 Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
08/11/2011	CA2788032A1 Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
08/11/2011	CA2788029A1 Sigma ligands for use in the prevention and/or treatment of postoperative pain
08/11/2011	CA2788024A1 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
08/11/2011	CA2787470A1 Combination composition, comprising as active ingredients l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency
08/11/2011	CA2787461A1 Polysaccharide based antimicrobial formulations
08/11/2011	CA2787360A1 Apoptosis signal-regulating kinase 1 inhibitors
08/11/2011	CA2787291A1 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
08/11/2011	CA2786927A1 Pharmaceutically acceptable salts of pyrrolo-nitrogenous heterocyclic derivatives, preparation method and medical use thereof
08/11/2011	CA2786428A1 Branched soluble glucose polymers for peritoneal dialysis
08/11/2011	CA2785776A1 Tetrahydro-pyran derivatives against neurological illnesses
08/11/2011	CA2692371A1 Anti-fatigue composition
08/10/2011	EP2354255A1 Methods for optimizing clinical responsiveness to methrotrexate therapy using metabolite profiling
08/10/2011	EP2354230A1 Neisseria meningitidis surface protein
08/10/2011	EP2354213A1 Reduction of sterols and other compounds from oils
08/10/2011	EP2354155A2 Fusion Proteins for Treatment of CNS
08/10/2011	EP2354148A2 Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
08/10/2011	EP2354147A2 10-substituted macrolide antibiotics
08/10/2011	EP2354144A1 Crystals of quinolinecarboxylic acid derivative solvate
08/10/2011	EP2354141A1 (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.
08/10/2011	EP2354140A1 Pyrrolopyridines useful as inhibitors of protein kinase
08/10/2011	EP2354139A1 Pyrrolopyridines useful as inhibitors of protein kinase
08/10/2011	EP2354136A1 Novel dopamine d3 receptor ligands, the preparation and use thereof
08/10/2011	EP2354134A1 2h-chromene compound and derivative thereof
08/10/2011	EP2354126A1 Heteroaryl sulfonamides and CCR2
08/10/2011	EP2354125A1 Anhydrous and hydrate polymorphic forms of antihistaminic piperidine derivatives

1 ... 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 ... 7860